Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04862663 · ClinicalTrials.gov registry record · Phase 3
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
A Phase 3 study of Locally Advanced (Inoperable) or Metastatic Breast Cancer, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 895
- Enrollment target
- 20
- Study locations
NCT04862663 is a Phase 3 study of Locally Advanced (Inoperable) or Metastatic Breast Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 895 participants. The trial reports 20 study locations across 10 states.
The verdict
NCT04862663, a Phase 3 study of Locally Advanced (Inoperable) or Metastatic Breast Cancer, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 895 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Phase Ib/III Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)
Conditions Studied
Interventions
- DRUG Fulvestrant
- DRUG Palbociclib
- DRUG Abemaciclib
- DRUG Ribociclib
- DRUG Capivasertib
Study Locations (20)
California
- Research Site - Fountain Valley
- Research Site - Glendale
- Research Site - Los Angeles
- Research Site - Los Angeles
- Research Site - Napa
- Research Site - Newport Beach
- Research Site - San Francisco
- Research Site - Santa Barbara
- Research Site - Santa Rosa
Kentucky
- Research Site - Louisville
- Research Site - Louisville
Louisiana
- Research Site - Baton Rouge
- Research Site - Covington
Arizona
- Research Site - Tucson
Colorado
- Research Site - Aurora
Connecticut
- Research Site - New Haven
Delaware
- Research Site - Newark
Illinois
- Research Site - Quincy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 895 participants |
| Start Date | 2021-05-10 |
| Est. Completion | 2029-08-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04862663
The ClinicalTrials.gov registry entry for NCT04862663 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 895 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Locally Advanced (Inoperable) or Metastatic Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Fulvestrant is the first listed.
NCT04862663 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Kentucky, Louisiana.
Frequently Asked Questions
What is clinical trial NCT04862663 about?
NCT04862663 is a clinical study titled "Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)". A Phase Ib/III Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)
What is the current status of trial NCT04862663?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 895 participants. The study started on 2021-05-10. Estimated completion is 2029-08-14.
What conditions does trial NCT04862663 study?
This clinical trial studies the following conditions: Locally Advanced (Inoperable) or Metastatic Breast Cancer.
What interventions are being tested in trial NCT04862663?
The interventions under investigation include: Fulvestrant (DRUG), Palbociclib (DRUG), Abemaciclib (DRUG), Ribociclib (DRUG), Capivasertib (DRUG).
Who is sponsoring clinical trial NCT04862663?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04862663 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Locally Advanced (Inoperable) or Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.